Fewer than 10% of people who could benefit from weight-loss injections including Wegovy are able to get them, states the global health agency as it publishes its first guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer access to this class of drugs.
Based on estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be managed with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the treatments that can assist patients in reducing considerable weight, notes the agency.
Skinny Jab Supply Crisis
Despite the current most favorable case, the supply of these medications might only reach around 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation calls on countries and companies to increase availability, through strategies like patent sharing.
A patent on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Obesity Injections Function
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so individuals eat less.
Individuals usually start to lose weight after several weeks of commencing the regular doses.
Research points to patients may put most of the weight back on a year later of discontinuing the treatment, because their usual hunger return.
To be carrying excess weight raises your risk for experiencing health problems, like diabetes, heart disease, stroke, and specific cancers.
Excess weight concerns people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the WHO.
